LY-404187
LY-404187 is a potent and selective AMPAR potentiator. It has been shown to have potential use in the treatment of schizophrenia and related conditions, and has been investigated for its nootropic effects.
Pharmacology[edit]
LY-404187 is a potent and selective AMPA receptor potentiator, which means it enhances the activity of the AMPA receptor. The AMPA receptor is one of the three main types of ionotropic glutamate receptors, and it plays a key role in the fast synaptic transmission of excitatory signals in the brain.
LY-404187 has been shown to have potential use in the treatment of schizophrenia and related conditions. Schizophrenia is a chronic and severe mental disorder that affects how a person thinks, feels, and behaves. It is characterized by distortions in thinking, perception, emotions, language, sense of self, and behavior.
In addition to its potential use in the treatment of schizophrenia, LY-404187 has also been investigated for its nootropic effects. Nootropics, also known as "smart drugs", are substances that can improve cognitive function, particularly executive functions, memory, creativity, or motivation, in healthy individuals.
Clinical Trials[edit]
LY-404187 has undergone clinical trials to evaluate its safety and efficacy in the treatment of schizophrenia. The results of these trials have shown that LY-404187 is safe and well-tolerated, and it has demonstrated potential efficacy in improving the cognitive deficits associated with schizophrenia.
See Also[edit]
References[edit]
This WikiMD article can only be edited by registered and verified editors. You can log in or register.
-
LY-404187
Sponsored Health Resource
W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
